Pages

• Antiplatelets/Anticoagulants
  • Practical Considerations for Use of Oral Antithrombotic Agents (Antiplatelets and Anticoagulants)
  • Protocol for Use of Oral Antithrombotic Agents (Antiplatelets and Anticoagulants)
• Contact
• Diabetes Self-Management Education and Support
  • Prescribing Insulin and Diabetes Supplies: Quick Reference
• GLP-1 RA
  • Practical Considerations for Use of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA)
  • Protocol for Use of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA)
• Health Screening
  • Risk Assessment Tools and Health Screening Instruments Commonly Used in Cardiometabolic Patients
• Home
• Insulin and Additional Oral Medication Resources
  • Insulin and Insulin Secretagogues – Considerations When Initiating a New Glucose-Lowering Medication
  • Other Medications Commonly Used in Treating Cardiometabolic Patients
  • Protocol for Titration of Insulin and Insulin Secretagogues When Initiating a GLP-1 RA
  • Protocol for Titration of Insulin and Insulin Secretagogues When Initiating a SGLT2i
• IT and Registry Management
  • CMCA Metrics and Benchmark Reporting
  • Quick-Phrase and Provider Visit Documentation Examples
• News
  • Newsletters
  • Press Releases
• Onboarding Tools
  • Building Teams
  • Implementing Clinical Pharmacist Services
• Operational Resources
  • Manufacturer Contact List
  • Program Operation Best Practices for Medical Office Support
  • SBAR Template for Triaging Patients with Diabetes
  • SBAR Template for Triaging Patients with Heart Failure
• PCSK9i
  • Practical Considerations for Use of Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors (PCSK9i) in Cardiometabolic Disease
  • Protocol for Use of Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors (PCSK9i)
• Privacy Policy
• RAASi
  • Practical Considerations for Use of Renin-Angiotensin-Aldosterone System Inhibitors in Cardiometabolic Disease (RAASi: ACE-I, ARB, ARNI, MRA)
  • Protocol for Use of Renin-Angiotensin-Aldosterone System Inhibitors in Cardiometabolic Disease (RAASi: ACE-I, ARB, ARNI, MRA)
• Search
• SGLT2i
  • Practical Considerations for Use of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)
  • Protocol for Use of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)
• Statins
  • Practical Considerations for Use of HMG-CoA Reductase Inhibitors (Statins)
  • Protocol for Use of HMG-CoA Reductase Inhibitors (Statins)
• Terms of Use

Press Releases

• Amgen becomes a Supporting Sponsor of the Cardiometabolic Center Alliance
• Atlantic Health System joins the Cardiometabolic Center Alliance as a Charter Member, 1st in NJ
• Atrium Health Wake Forest Baptist Joins the Cardiometabolic Center Alliance as a Charter Member
• Baptist Health South Florida Joins the Cardiometabolic Center Alliance as a Charter Member 
• Bryan Heart Joins the Cardiometabolic Center Alliance as a Charter Member
• CMCA Executive Director Presents Late Breaking Clinical Trial
• Essentia Health Joins the Cardiometabolic Center Alliance as a Charter Member
• Major Health Partners Joins the Cardiometabolic Center Alliance as a Charter Member
• MedStar Health Joins the Cardiometabolic Center Alliance as a Charter Member
• Northwell Health Joins the Cardiometabolic Center Alliance as a Charter Member
• Our Lady of the Lake Heart & Vascular Institute Joins the Cardiometabolic Center Alliance as a Charter Member
• Rochester Regional Health Joins the Cardiometabolic Center Alliance as a Charter Member
• Saint Luke’s Mid America Heart Institute Announces Launch of National Cardiometabolic Center Alliance
• The Cardiometabolic Center Alliance Announces Boehringer Ingelheim as a Sponsor
• TriHealth Joins the Cardiometabolic Center Alliance as a Charter Member
• University Hospitals Cleveland Medical Center Joins as a Key Strategic Partner and Charter Member
• University of Mississippi Medical Center Joins the Cardiometabolic Center Alliance as a Charter Member
• Video: Launch of Cardiometabolic Center Alliance